Kapat
Popüler Videolar
Moods
Türler
English
Türkçe
Popüler Videolar
Moods
Türler
Turkish
English
Türkçe
Unmet needs in second-line DLBCL and challenges in this space
1:16
|
Loading...
Download
Lütfen bekleyiniz...
Type
Size
İlgili Videolar
Unmet needs in second-line DLBCL and challenges in this space
1:16
|
Novel strategies emerging for elderly patients with DLBCL and ongoing trials in this space
3:09
|
Treatment approaches for patients with R/R DLBCL: UK perspective
2:28
|
Insights into rapid CAR-T manufacturing processes and challenges in this space
1:19
|
Managing early & late relapse after first-line therapy for DLBCL
1:39
|
New data on DLBCL in the UK and its impact on treatment decisions
6:33
|
CLL: Combination Strategies and Unmet Needs
2:33
|
Is Stem Cell Transplantation Still a Treatment Option for Some DLBCL Patients?
2:23
|
The value of CAR-T cell therapy in R/R DLBCL
0:51
|
Novel treatment approaches for early-stage DLBCL
2:03
|
Glofitamab as a single agent in heavily pretreated patients with DLBCL
2:33
|
Pitfalls in the diagnosis of lymphoid malignancies: interpreting PET scans
1:01
|
Management and outcomes of elderly patients with LBCL
1:32
|
Improving patient outcomes in CTCL: clinical collaboration and novel agents
1:20
|
Treatment options for DLBCL patients who relapse after CAR-T cell therapy
1:55
|
The use of PET and ctDNA for risk stratification & to guide treatment decisions in Hodgkin lymphoma
2:32
|
Updates in the treatment of R/R LBCL: promising novel agents in the pipeline
1:18
|
Treatment options for patients with DLBCL who relapse after CAR-T therapy
2:14
|
The promise of CD30-targeting cellular therapies in HL
0:51
|
Elderly DLBCL updates
2:04
|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa
